Publications by authors named "K Kiura"
Blood-based predictive markers for the efficacy of immune checkpoint inhibitors (ICIs) have not yet been established. We investigated the association of the plasma level of S100A8/A9 with the efficacy of immunotherapy. We evaluated patients with unresectable stage III/IV or recurrent non-small cell lung cancer (NSCLC) who were treated with ICIs at Okayama University Hospital.
View Article and Find Full Text PDFLimited data are available on the frequency and significance of body weight loss during cancer therapy. This study investigated the frequency of patients who experienced body weight loss during immune checkpoint inhibitor (ICI) plus chemotherapy for advanced non-small cell lung cancer (NSCLC) and the impact of weight loss on treatment outcomes. Using the clinical data of 370 patients with NSCLC who received a combination of ICI and chemotherapy at 13 institutions, this study investigated the frequency of body weight loss > 5% during treatment and determined the impact of body weight loss on patient outcomes.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness of immune checkpoint inhibitors (ICI) for non-small cell lung cancer (NSCLC) patients, particularly comparing those with brain metastases (BM) to those without.
- It analyzes data from 240 patients, finding no major overall survival differences between the two groups, but identifies a significant survival disadvantage for patients with BM among those with high PD-L1 expression (≥50%).
- The conclusion suggests that while ICI is generally effective for both groups, patients with BM and high PD-L1 levels may have poorer outcomes compared to their counterparts without BM.
Backgrounds: To the best of our knowledge, there are no reports of proteomic analysis for the identification of unknown proteins involved in resistance to anaplastic lymphoma kinase (ALK) inhibitors. In this study, we investigated the proteins involved in resistance to alectinib, a representative ALK inhibitor, through proteomic analysis and the possibility of overcoming resistance.
Methods: An ALK-positive lung adenocarcinoma cell line (ABC-11) and the corresponding alectinib-resistant cell line (ABC-11/CHR2) were used.
The combined inhibition of SLC1A3 and glutaminase in osimertinib-resistant EGFR mutant cells.
Biochim Biophys Acta Gen Subj
October 2024
Article Synopsis
- Researchers studied osimertinib-resistant EGFR-mutant lung cancer to uncover the resistance mechanisms using specialized cell lines developed through exposure to the drug.
- They found that SLC1A3, a transporter for glutamic acid, was significantly more active in resistant cells, and targeting it with specific inhibitors increased drug sensitivity.
- The results suggest that combining osimertinib with a glutaminase inhibitor could effectively counteract resistance and improve treatment outcomes for patients with this type of lung cancer.